SG11201806587RA - Mesenchymal stem cells as vaccine adjuvants and methods for using the same - Google Patents
Mesenchymal stem cells as vaccine adjuvants and methods for using the sameInfo
- Publication number
- SG11201806587RA SG11201806587RA SG11201806587RA SG11201806587RA SG11201806587RA SG 11201806587R A SG11201806587R A SG 11201806587RA SG 11201806587R A SG11201806587R A SG 11201806587RA SG 11201806587R A SG11201806587R A SG 11201806587RA SG 11201806587R A SG11201806587R A SG 11201806587RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- mesenchymal stem
- cells
- pct
- vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55588—Adjuvants of undefined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111010111110111011100110111011001101111101111011111 International Bureau 0.. .... .. ...... ... (10) International Publication Number International Publication Date WO 2017/136539 Al 10 August 2017(10.08.2017) WIPO I PCT (51) (21) (22) (25) Filing Language: (26) Publication Language: (30) (72) (71) (74) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, A61K 35/28 (2015.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, Fk GB, GD, GE, GH, GM, GT, International Application Number: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, PCT/US2017/016200 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, International Filing Date: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, 2 February 2017 (02.02.2017) NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, English ZA, ZM, ZW. Priority Data: (84) Designated States (unless otherwise indicated, for every 62/291,350 4 February 2016 (04.02.2016) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, Inventors; and TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Applicants : HARE, Joshua M. [US/US]; c/o Longever- TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, on LLC, 1951 NW 7th Avenue, Suite 300, Miami, Florida DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, 33136 (US). LANDIN, Ana Marie [US/US]; c/o Univer- LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, sity of Miami, 1320 South Dixie Highway, Gables One SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Tower, Suite 650, Coral Gables, Florida 33146 (US). GW, KM, ML, MR, NE, SN, TD, TG). Agents: HANSEN, Christine M. et al.; Buchanan Inger- Published: soli & Rooney PC, P.O. Box 1404, Alexandria, Virginia — with international search report (Art. 21(3)) 22313-1404 (US). — with amended claims (Art. 190)) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (81) = (54) Title: MESENCHYMAL STEM 15 _c c. E , co 0 -5 to C' 8 --15 cS 0 co 2 u) -25 E - r n ' 0 0 _ 0 -35 = T i; -45 . 7 =C -55 : The present invention a population of isolated allogeneic human mesenchymal stem cells. The present invention also provides kits comprising a vac - in a first container and a population of isolated allogeneic human mesenchymal stem cells in a second container. CI' 0 CELLS AS VACCINE ADJUVANTS AND METHODS FOR USING THE SAME r 2 =0.73 p<0.00001 1-1 cr) kr) cr) ,-, IN 1-1 (57) N and cm • e 10 20 30 40 50 60 70 %CD25 Cells Gated on CD3 Cells at Baseline FIG. 5D provides a method of enhancing an immune response to a vaccine by administering a vaccine
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291350P | 2016-02-04 | 2016-02-04 | |
| PCT/US2017/016200 WO2017136539A1 (en) | 2016-02-04 | 2017-02-02 | Mesenchymal stem cells as vaccine adjuvants and methods for using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806587RA true SG11201806587RA (en) | 2018-09-27 |
Family
ID=58261704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806587RA SG11201806587RA (en) | 2016-02-04 | 2017-02-02 | Mesenchymal stem cells as vaccine adjuvants and methods for using the same |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11975068B2 (en) |
| EP (2) | EP4316497A3 (en) |
| JP (2) | JP2019509264A (en) |
| KR (1) | KR20180105705A (en) |
| AU (2) | AU2017213812B2 (en) |
| CA (1) | CA3013457A1 (en) |
| ES (1) | ES2960206T3 (en) |
| IL (1) | IL260858B (en) |
| SG (1) | SG11201806587RA (en) |
| WO (1) | WO2017136539A1 (en) |
| ZA (2) | ZA201805159B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020166063A1 (en) * | 2019-02-15 | 2020-08-20 | 大和薬品株式会社 | Method for improving frailty and food for improving frailty |
| CN111568927A (en) * | 2020-05-23 | 2020-08-25 | 湖南源品细胞生物科技有限公司 | Application of MSC (mesenchymal stem cell) in regulating number of memory B cells |
| CA3194052A1 (en) | 2020-09-08 | 2022-03-17 | Longeveron, Inc. | Treatment of alzheimer's disease with allogeneic mesenchymal stem cells |
| CN112641938A (en) * | 2020-11-22 | 2021-04-13 | 翁炳焕 | DNA recombinant stem cell vector new corona vaccine |
| TW202321437A (en) | 2021-07-26 | 2023-06-01 | 美商生命科學股份有限公司 | Use of mesenchymal stem cells in treatment of juvenile hypoplastic left heart syndrome |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1066060E (en) | 1998-04-03 | 2003-12-31 | Osiris Therapeutics Inc | MESENCHINEAL STAMINA CELLS AS IMMUNOSUPRESSORS |
| US8554280B2 (en) | 2010-03-23 | 2013-10-08 | Ebay Inc. | Free-form entries during payment processes |
| US10472647B2 (en) | 2012-12-21 | 2019-11-12 | The Administrators Of The Tulane Educational Fund | Primary mesenchymal stem cells as a vaccine platform |
| WO2014100857A1 (en) | 2012-12-24 | 2014-07-03 | Cell Ideas Pty Ltd | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy |
| US9101597B2 (en) | 2013-03-14 | 2015-08-11 | The Administration Of The Tulane Educational Fund | Immunoprotective primary mesenchymal stem cells and methods |
| CN104138391B (en) * | 2013-05-08 | 2018-07-31 | 中国科学院上海生命科学研究院 | Application of the mescenchymal stem cell in preventing or treating immunity degradation caused by stress reaction |
-
2017
- 2017-02-02 KR KR1020187025027A patent/KR20180105705A/en active Search and Examination
- 2017-02-02 SG SG11201806587RA patent/SG11201806587RA/en unknown
- 2017-02-02 AU AU2017213812A patent/AU2017213812B2/en active Active
- 2017-02-02 WO PCT/US2017/016200 patent/WO2017136539A1/en active Application Filing
- 2017-02-02 CA CA3013457A patent/CA3013457A1/en active Pending
- 2017-02-02 EP EP23199388.2A patent/EP4316497A3/en active Pending
- 2017-02-02 ES ES17709498T patent/ES2960206T3/en active Active
- 2017-02-02 US US16/075,276 patent/US11975068B2/en active Active
- 2017-02-02 EP EP17709498.4A patent/EP3411050B1/en active Active
- 2017-02-02 JP JP2018541195A patent/JP2019509264A/en active Pending
-
2018
- 2018-07-30 IL IL260858A patent/IL260858B/en unknown
- 2018-07-31 ZA ZA2018/05159A patent/ZA201805159B/en unknown
-
2020
- 2020-01-29 ZA ZA2020/00574A patent/ZA202000574B/en unknown
-
2023
- 2023-01-05 JP JP2023000567A patent/JP2023036949A/en active Pending
-
2024
- 2024-04-08 US US18/629,427 patent/US20240252627A1/en active Pending
- 2024-07-03 AU AU2024204598A patent/AU2024204598A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL260858A (en) | 2018-10-31 |
| CA3013457A1 (en) | 2017-08-10 |
| EP3411050B1 (en) | 2023-09-27 |
| WO2017136539A1 (en) | 2017-08-10 |
| US20240252627A1 (en) | 2024-08-01 |
| AU2024204598A1 (en) | 2024-07-18 |
| EP3411050A1 (en) | 2018-12-12 |
| US11975068B2 (en) | 2024-05-07 |
| ZA202000574B (en) | 2021-08-25 |
| AU2017213812B2 (en) | 2024-04-04 |
| ES2960206T3 (en) | 2024-03-01 |
| JP2019509264A (en) | 2019-04-04 |
| IL260858B (en) | 2022-04-01 |
| JP2023036949A (en) | 2023-03-14 |
| AU2017213812A1 (en) | 2018-08-16 |
| EP4316497A3 (en) | 2024-05-01 |
| EP4316497A2 (en) | 2024-02-07 |
| US20190038742A1 (en) | 2019-02-07 |
| KR20180105705A (en) | 2018-09-28 |
| ZA201805159B (en) | 2020-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806587RA (en) | Mesenchymal stem cells as vaccine adjuvants and methods for using the same | |
| SG11201803703UA (en) | Anti-complement factor c1q fab fragments and uses thereof | |
| SG11201910096RA (en) | Anti-cd3-binding domains and antibodies comprising them, and methods for their generation and use | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201807426WA (en) | Immunomodulators | |
| SG11201907870VA (en) | Compositions and methods for inhibition of lineage specific proteins | |
| SG11201900772YA (en) | Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors | |
| SG11201907857RA (en) | Edible and biodegradable utensils | |
| SG11201903697WA (en) | Liver organoid compositions and methods of making and using same | |
| SG11201809614VA (en) | Method for the fabrication of three-dimensional objects and apparatus for same | |
| SG11201806150RA (en) | Psma and cd3 bispecific t cell engaging antibody constructs | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201806988UA (en) | Improved differentiation method | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201906487TA (en) | Service data processing method and device, and service processing method and device | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201804710TA (en) | Devices for simulating a function of a liver tissue and methods of use and manufacturing thereof | |
| SG11201811292RA (en) | Compositions and methods for the depletion of cells | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201807809XA (en) | A transient commensal microorganism for improving gut health | |
| SG11201407819UA (en) | Improved methods of cell culture for adoptive cell therapy | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201810466PA (en) | Compositions and methods related to engineered fc constructs |